Inhaled zanamivir for the prevention of influenza in families

New England Journal of Medicine

Volumn 343, Issue 18, 2000, Pages 1282-1289

  Hayden, Frederick G ^a,f   Gubareva, Larisa V ^a   Monto, Arnold S ^b   Klein, Thomas C ^c   Elliott, Michael J ^d   Hammond, Janet M ^d   Sharp, Stephen J ^e   Ossi, Michael J ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Heartland Research   (United States)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; PLACEBO; RIMANTADINE; SIALIDASE; ZANAMIVIR;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FAMILY HEALTH; FEMALE; HOUSEHOLD; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASON; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; FAMILY HEALTH; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; PROSPECTIVE STUDIES; PYRANS; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; SIALIC ACIDS; ZANAMIVIR;

EID: 0034597724     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200011023431801     Document Type: Article

References (28)

1. Estimating household and community transmission parameters for influenza
2. Amantadine, rimantadine, and related agents
3. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
4. Protective effect of 1-adamantanamine hydrochtoride on influenza A2 infections in the family environment: A controlled double-blind study
5. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment
6. Prevention de la grippe A: Efficacite et tolerance du chtorhydrate de rimantadine
7. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections
8. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
9. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study
10. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
11. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996
12. The quantitative determination of influenza virus and antibodies by means of red cell agglutination
13. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
14. Fluoromettic assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N-acetylneuraminate) substrate
15. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
16. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
17. Point and interval estimation of the common odds ratio in the combination of 2x2 tables with fixed marginals
18. A simple example of a comparison inolving quantal data Biometrika
19. Clinical efficacy trials with categorical data
20. Fixing the number of events in large comparative trials with low event rates: A binomial approach
21. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine
22. Recovert of drug-resistant influenza A virus during therapeutic use of rimantadine
23. Children with influenza A infection: Treatment with rimantadine
24. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults
25. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
26. Zanamivir for treatment of symptomatic influenza A and B infection in children 5 to12 years of age: A randomized controlled trial
27. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers